Developer docs
API playgroundTry for free, no card

Search company profiles

Apertura Gene Therapy

Full company profile

uuid00035nq

Namestring
Apertura Gene Therapy
Legal namestring
Apertura Gene Therapy
Websiteurl
aperturagtx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Apertura Gene Therapy offers treatment options for debilitating diseases with few options. It is in a unique position to develop genetic medicines by simultaneously engineering AAV capsids, regulatory elements, and payloads to overcome current gene therapy limitations. They are dedicated to the advancement of gene therapy and believe that by collaborating with corporate and academic partners, patients, and disease.

Short descriptiontext

Apertura Gene Therapy is a biotechnology company that treats debilitating diseases with limited options.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewyork, United Kingdom
HQ citystring
Newyork
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy delivery, AAV capsid engineering, CNS targeted therapeutics, blood-brain barrier delivery, capsid licensing platform
Industry3 codes
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy Technology / AAV Capsid Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Manufacturing Services
TypeProfessional Services
Description

Through partnership with Viralgen CDMO, supporting clinical manufacturing of gene therapies using TfR1 CapX for Apertura's licensees.

prnewswire.com
2Academic Access Program
TypeLicensing Royalties
Description

Open Aperture MTA program provides no-cost access to academic researchers for non-commercial research, potentially leading to future licensing opportunities.

prnewswire.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of TfR1 CapX and other capsid technologies to biopharma companies and patient advocacy organizations for development of CNS gene therapies. Partners include Galibra Neuroscience, Emugen Therapeutics, AviadoBio, and others.

deerfield.com
4Collaboration and Development Agreements
TypeLicensing Royalties
Description

Strategic collaborations with patient advocacy organizations, academic institutions, and government agencies (NIH CRADA, ARPA-H consortium) that may include milestone payments, research funding, and development support.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Apertura Gene Therapy develops and licenses proprietary AAV capsid technology, principally TfR1 CapX, that crosses the blood-brain barrier to enable intravenous delivery of genetic medicines to the central nervous system. The company operates a platform that combines machine-learning-guided capsid engineering, genetic regulatory element design, and payload optimization, and monetizes this platform through licensing deals, strategic collaborations, and internal gene therapy programs targeting rare CNS disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 50% neuronal transduction and 90% astrocyte transduction across multiple brain regions in preclinical studies
+3 more records
Product overview1 text field

Apertura Gene Therapy is a biotechnology company developing genetic medicines through a platform approach that simultaneously engineers AAV capsids, genetic regulatory elements, and payloads. The core product is TfR1 CapX, a next-generation AAV capsid that crosses the blood-brain barrier via human transferrin receptor 1 targeting. Supporting platforms include the Fit4Function capsid engineering platform (using machine learning for multi-trait optimization) and the GRE platform for cell type-specific expression. The Open Aperture program provides academic researchers no-cost access to TfR1 CapX for non-commercial research. The company operates both internal pipeline programs (including TSC1/TSC2 programs) and partners with external organizations for various CNS disease programs.

Product and service3 records
1TfR1 CapX
CategoryAAV capsid delivery technology
2Open Aperture Program
CategoryAcademic access program
3TSC1/TSC2 Gene Therapy Programs
CategoryInternal pipeline program
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Foundation for Angelman Syndrome Therapeutics (FAST)
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-08-05
Description

Agreement for access to TfR1 CapX for Angelman syndrome gene therapy research and development programs. FAST is the leading patient advocacy organization for Angelman syndrome, affecting approximately 1 in 15,000 people.

aperturagtx.com
2ARPA-H THRIVE Program Consortium
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-07-23
Description

Part of consortium led by Broad Institute's Center for Therapeutic Genetics selected for ARPA-H THRIVE funding. Developing gene therapies for rare childhood diseases affecting 3M+ children. Uses TfR1 CapX with base and prime gene editing technologies. Manufacturing support from Viralgen.

aijourn.com
3NIH (NICHD and NHGRI)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-07-09
Description

CRADA collaboration to test gene therapy for Niemann-Pick Disease Type C1 using TfR1 CapX. Multi-year research with funding support from Ara Parseghian Medical Research Fund. Goal to advance through regulatory review and manufacturing.

yahoo.com
4TSC Alliance
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Collaboration to advance TSC1 and TSC2 gene therapy programs using TfR1 CapX for tuberous sclerosis complex. Leverages TSC Alliance Preclinical Consortium infrastructure. Committed to raise $1.76M over 18 months for preclinical evaluation.

prnewswire.com
5AviadoBio
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-04-27
Description

Licensed TfR1 CapX for use with vMiX RNAi platform. Developing AVB-406 for Alzheimer's disease and other tauopathies. Headquartered in London with US operations.

aperturagtx.com
6Broad Institute Scientists
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Ongoing collaboration with scientists including Ben Deverman and Sonia Vallabh for presentations at ASGCT and joint development of gene therapy approaches (prion disease, base editing strategies).

prnewswire.com
7Viralgen
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Strategic manufacturing collaboration. Viralgen provides GMP manufacturing services including plasmid production, fill-finish, and quality control testing for TfR1 CapX. Leverages its integrated AAV manufacturing platform with established production framework deployed across 1,500+ batches. Supports clinical-scale production for Apertura's licensees.

prnewswire.com
8Finding Hope for Frizzle (FRRS1L)
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-18
Description

License agreement for gene therapy development targeting FRRS1L disease (early infantile epileptic encephalopathy type 37). Parent-led nonprofit planning clinical trial in 2H 2026, pending regulatory approval.

prnewswire.com
9Galibra Neuroscience
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-08-13
Description

Licensed TfR1 CapX for GABA-related disorders including succinic semialdehyde dehydrogenase deficiency (SSADHD). Co-founded by researchers at Boston Children's Hospital and Harvard Medical School.

prnewswire.com
10Emugen Therapeutics
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-08-13
Description

Licensed TfR1 CapX for neurodevelopmental and neurodegenerative disease programs. Founded by academic founders from Broad Institute, Harvard and MIT.

prnewswire.com
11Rett Syndrome Research Trust (RSRT)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

Collaboration to license TfR1 CapX for genetic medicines targeting Rett syndrome. RSRT's MECP2 Editing Consortium (six labs) will utilize the capsid under $40M Roadmap to Cures initiative targeting three genetic medicines in clinical trials by 2028.

prnewswire.com
12Whitehead Institute
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-02-28
Description

Collaboration on prion disease gene therapy combining Apertura's TfR1 capsid with CHARM epigenetic editing platform from Jonathan Weissman's lab. Vallabh-Minikel lab at Broad leads the project.

aperturagtx.com
13Broad Institute of MIT and Harvard
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-26
Description

Core technology source. Company founded on platform technologies developed by Ben Deverman, Ph.D. at the Broad Institute's Vector Engineering Lab. Apertura holds exclusive rights to AAV capsids developed in the Deverman Lab. Collaborates on ongoing research and presentations at scientific conferences.

aperturagtx.com
14Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-26
Description

Technology source for genetic regulatory elements. Sponsored research and licensing agreement with Harvard University (through Office of Technology Development) grants Apertura exclusive access to methods of identifying cell type-specific GREs, including the PESCA platform developed by Michael Greenberg, Ph.D.

aperturagtx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
14D Molecular Therapeutics (4DMT)
TypeDirect peer
Description

Clinical-stage gene therapy company developing targeted AAV vectors using its Therapeutic Vector Evolution platform for tissue-specific delivery, with multiple CNS and other tissue programs in the clinic. Direct competitor in receptor-targeted AAV capsid engineering for CNS and beyond.

2Voyager Therapeutics
TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV capsid engineering (TRACER platform) for CNS diseases including Parkinson's, Huntington's, and Alzheimer's. Closest direct competitor to Apertura in receptor-targeted CNS AAV capsid development.

3Dyno Therapeutics
TypeDirect peer
Description

AI-driven AAV capsid engineering company partnering with Novartis and Roche for CNS, muscle, and eye-directed gene therapies. Direct competitor using machine learning for capsid design, analogous to Apertura's Fit4Function platform.

4Taysha Gene Therapies
TypeDirect peer
Description

Clinical-stage CNS gene therapy company developing AAV-based therapies for rare monogenic neurological diseases. Comparable indication focus and AAV delivery model, though with less proprietary capsid engineering.

5Lexeo Therapeutics
TypeDirect peer
Description

Clinical-stage gene therapy company focused on CNS disorders and cardiac diseases using AAV delivery, with programs in Alzheimer's, Friedreich's ataxia, and Rett syndrome. Competes for the same biopharma partners and disease indications.

6Latus Bio
TypeEmerging player
Description

Early-stage gene therapy company developing AAV-based treatments for CNS disorders using novel capsid engineering. Emerging competitor with partial overlap on indication focus and delivery platform approach.

7Denali Therapeutics
TypeBroad incumbent
Description

Clinical-stage neurodegenerative disease company with proprietary BBB-crossing delivery technology (OTV platform) and broad CNS pipeline. Larger incumbent operating across multiple CNS modalities with overlapping capsid/delivery science.

8BioMarin Pharmaceutical
TypeBroad incumbent
Description

Established commercial-stage gene therapy company with FDA-approved CNS gene therapy (Roctavian for hemophilia A; prior CNS programs). Broad incumbent in gene therapy commercialization with adjacent delivery expertise.

9uniQure
TypeBroad incumbent
Description

Commercial-stage gene therapy company with FDA-approved AAV therapy (Hemgenix for hemophilia B) and CNS pipeline (Huntington's, ALS). Comparable platform-based AAV development model with broader indication footprint.

10AviadoBio
TypeEmerging player
Description

Clinical-stage AAV gene therapy company developing AVB-406 for Alzheimer's and tauopathies, currently licensing Apertura's TfR1 CapX combined with its own vMiX RNAi platform. Functions as both partner and adjacent competitor in CNS AAV gene therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apertura Gene Therapy

Gene Therapy Technology / AAV Capsid Platformaperturagtx.com

Apertura Gene Therapy is a biotechnology company that treats debilitating diseases with limited options.

What Apertura Gene Therapy does

Apertura Gene Therapy offers treatment options for debilitating diseases with few options. It is in a unique position to develop genetic medicines by simultaneously engineering AAV capsids, regulatory elements, and payloads to overcome current gene therapy limitations. They are dedicated to the advancement of gene therapy and believe that by collaborating with corporate and academic partners, patients, and disease.

Apertura Gene Therapy firmographics

Firmographics
Name
Apertura Gene Therapy
Legal name
Apertura Gene Therapy
Website
https://aperturagtx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Apertura Gene Therapy is a biotechnology company that treats debilitating diseases with limited options.
Ownership category
akta.pro rank

Apertura Gene Therapy industry classification

Industry
Product category
Gene Therapy Technology / AAV Capsid Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Gene therapy delivery
  • AAV capsid engineering
  • CNS targeted therapeutics
  • Blood-brain barrier delivery
  • Capsid licensing platform

Where Apertura Gene Therapy is headquartered

Location

Headquarters

HQ city
Newyork
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Apertura Gene Therapy business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Manufacturing Services: Through partnership with Viralgen CDMO, supporting clinical manufacturing of gene therapies using TfR1 CapX for Apertura's licensees.
  2. Academic Access Program: Open Aperture MTA program provides no-cost access to academic researchers for non-commercial research, potentially leading to future licensing opportunities.
  3. Technology Licensing: Licensing of TfR1 CapX and other capsid technologies to biopharma companies and patient advocacy organizations for development of CNS gene therapies. Partners include Galibra Neuroscience, Emugen Therapeutics, AviadoBio, and others.
  4. Collaboration and Development Agreements: Strategic collaborations with patient advocacy organizations, academic institutions, and government agencies (NIH CRADA, ARPA-H consortium) that may include milestone payments, research funding, and development support.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Apertura Gene Therapy product offering

Product offering

Core offering

Apertura Gene Therapy develops and licenses proprietary AAV capsid technology, principally TfR1 CapX, that crosses the blood-brain barrier to enable intravenous delivery of genetic medicines to the central nervous system. The company operates a platform that combines machine-learning-guided capsid engineering, genetic regulatory element design, and payload optimization, and monetizes this platform through licensing deals, strategic collaborations, and internal gene therapy programs targeting rare CNS disorders.

Product overview

Apertura Gene Therapy is a biotechnology company developing genetic medicines through a platform approach that simultaneously engineers AAV capsids, genetic regulatory elements, and payloads. The core product is TfR1 CapX, a next-generation AAV capsid that crosses the blood-brain barrier via human transferrin receptor 1 targeting. Supporting platforms include the Fit4Function capsid engineering platform (using machine learning for multi-trait optimization) and the GRE platform for cell type-specific expression. The Open Aperture program provides academic researchers no-cost access to TfR1 CapX for non-commercial research. The company operates both internal pipeline programs (including TSC1/TSC2 programs) and partners with external organizations for various CNS disease programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • TfR1 CapX
  • Open Aperture Program
  • TSC1/TSC2 Gene Therapy Programs

Quantifiable outcome

  • Over 50% neuronal transduction and 90% astrocyte transduction across multiple brain regions in preclinical studies
  • +3 more outcomes

Companies that use Apertura Gene Therapy

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Apertura Gene Therapy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Apertura Gene Therapy partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered major, core and minor.

  • Foundation for Angelman Syndrome Therapeutics (FAST)majorOEM/ Whitelabel/ Licensing Partner · 5 August 2026Agreement for access to TfR1 CapX for Angelman syndrome gene therapy research and development programs. FAST is the leading patient advocacy organization for Angelman syndrome, affecting approximately 1 in 15,000 people.
  • ARPA-H THRIVE Program ConsortiummajorStrategic or Co-development Partner · 23 July 2026Part of consortium led by Broad Institute's Center for Therapeutic Genetics selected for ARPA-H THRIVE funding. Developing gene therapies for rare childhood diseases affecting 3M+ children. Uses TfR1 CapX with base and prime gene editing technologies. Manufacturing support from Viralgen.
  • NIH (NICHD and NHGRI)majorStrategic or Co-development Partner · 9 July 2026CRADA collaboration to test gene therapy for Niemann-Pick Disease Type C1 using TfR1 CapX. Multi-year research with funding support from Ara Parseghian Medical Research Fund. Goal to advance through regulatory review and manufacturing.
  • TSC AlliancemajorStrategic or Co-development Partner · 5 May 2026Collaboration to advance TSC1 and TSC2 gene therapy programs using TfR1 CapX for tuberous sclerosis complex. Leverages TSC Alliance Preclinical Consortium infrastructure. Committed to raise $1.76M over 18 months for preclinical evaluation.
  • AviadoBiomajorOEM/ Whitelabel/ Licensing Partner · 27 April 2026Licensed TfR1 CapX for use with vMiX RNAi platform. Developing AVB-406 for Alzheimer's disease and other tauopathies. Headquartered in London with US operations.
  • Broad Institute ScientistscoreStrategic or Co-development Partner · 27 April 2026Ongoing collaboration with scientists including Ben Deverman and Sonia Vallabh for presentations at ASGCT and joint development of gene therapy approaches (prion disease, base editing strategies).
  • ViralgencoreTechnology or Integration · 17 March 2026Strategic manufacturing collaboration. Viralgen provides GMP manufacturing services including plasmid production, fill-finish, and quality control testing for TfR1 CapX. Leverages its integrated AAV manufacturing platform with established production framework deployed across 1,500+ batches. Supports clinical-scale production for Apertura's licensees.
  • Finding Hope for Frizzle (FRRS1L)majorOEM/ Whitelabel/ Licensing Partner · 18 February 2026License agreement for gene therapy development targeting FRRS1L disease (early infantile epileptic encephalopathy type 37). Parent-led nonprofit planning clinical trial in 2H 2026, pending regulatory approval.
  • Galibra NeurosciencemajorOEM/ Whitelabel/ Licensing Partner · 13 August 2025Licensed TfR1 CapX for GABA-related disorders including succinic semialdehyde dehydrogenase deficiency (SSADHD). Co-founded by researchers at Boston Children's Hospital and Harvard Medical School.
  • Emugen TherapeuticsmajorOEM/ Whitelabel/ Licensing Partner · 13 August 2025Licensed TfR1 CapX for neurodevelopmental and neurodegenerative disease programs. Founded by academic founders from Broad Institute, Harvard and MIT.
  • Rett Syndrome Research Trust (RSRT)majorStrategic or Co-development Partner · 30 April 2025Collaboration to license TfR1 CapX for genetic medicines targeting Rett syndrome. RSRT's MECP2 Editing Consortium (six labs) will utilize the capsid under $40M Roadmap to Cures initiative targeting three genetic medicines in clinical trials by 2028.
  • Whitehead InstituteminorStrategic or Co-development Partner · 28 February 2025Collaboration on prion disease gene therapy combining Apertura's TfR1 capsid with CHARM epigenetic editing platform from Jonathan Weissman's lab. Vallabh-Minikel lab at Broad leads the project.
  • Broad Institute of MIT and HarvardcoreStrategic or Co-development Partner · 26 April 2022Core technology source. Company founded on platform technologies developed by Ben Deverman, Ph.D. at the Broad Institute's Vector Engineering Lab. Apertura holds exclusive rights to AAV capsids developed in the Deverman Lab. Collaborates on ongoing research and presentations at scientific conferences.
  • Harvard Medical SchoolcoreStrategic or Co-development Partner · 26 April 2022Technology source for genetic regulatory elements. Sponsored research and licensing agreement with Harvard University (through Office of Technology Development) grants Apertura exclusive access to methods of identifying cell type-specific GREs, including the PESCA platform developed by Michael Greenberg, Ph.D.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Apertura Gene Therapy competitors and assessment

Company assessment

Direct peers

  • 4D Molecular Therapeutics (4DMT): Clinical-stage gene therapy company developing targeted AAV vectors using its Therapeutic Vector Evolution platform for tissue-specific delivery, with multiple CNS and other tissue programs in the clinic. Direct competitor in receptor-targeted AAV capsid engineering for CNS and beyond.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV capsid engineering (TRACER platform) for CNS diseases including Parkinson's, Huntington's, and Alzheimer's. Closest direct competitor to Apertura in receptor-targeted CNS AAV capsid development.
  • Dyno Therapeutics: AI-driven AAV capsid engineering company partnering with Novartis and Roche for CNS, muscle, and eye-directed gene therapies. Direct competitor using machine learning for capsid design, analogous to Apertura's Fit4Function platform.
  • Taysha Gene Therapies: Clinical-stage CNS gene therapy company developing AAV-based therapies for rare monogenic neurological diseases. Comparable indication focus and AAV delivery model, though with less proprietary capsid engineering.
  • Lexeo Therapeutics: Clinical-stage gene therapy company focused on CNS disorders and cardiac diseases using AAV delivery, with programs in Alzheimer's, Friedreich's ataxia, and Rett syndrome. Competes for the same biopharma partners and disease indications.

Emerging players

  • Latus Bio: Early-stage gene therapy company developing AAV-based treatments for CNS disorders using novel capsid engineering. Emerging competitor with partial overlap on indication focus and delivery platform approach.
  • AviadoBio: Clinical-stage AAV gene therapy company developing AVB-406 for Alzheimer's and tauopathies, currently licensing Apertura's TfR1 CapX combined with its own vMiX RNAi platform. Functions as both partner and adjacent competitor in CNS AAV gene therapy.

Broad incumbents

  • Denali Therapeutics: Clinical-stage neurodegenerative disease company with proprietary BBB-crossing delivery technology (OTV platform) and broad CNS pipeline. Larger incumbent operating across multiple CNS modalities with overlapping capsid/delivery science.
  • BioMarin Pharmaceutical: Established commercial-stage gene therapy company with FDA-approved CNS gene therapy (Roctavian for hemophilia A; prior CNS programs). Broad incumbent in gene therapy commercialization with adjacent delivery expertise.
  • uniQure: Commercial-stage gene therapy company with FDA-approved AAV therapy (Hemgenix for hemophilia B) and CNS pipeline (Huntington's, ALS). Comparable platform-based AAV development model with broader indication footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Apertura Gene Therapy social profiles

Digital presence

Apertura Gene Therapy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apertura Gene Therapy leadership team

Management profile

Number of profiles

Profiles8 records

Apertura Gene Therapy funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apertura Gene Therapy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apertura Gene Therapy

What does Apertura Gene Therapy do?

Apertura Gene Therapy develops and licenses proprietary AAV capsid technology, principally TfR1 CapX, that crosses the blood-brain barrier to enable intravenous delivery of genetic medicines to the central nervous system. The company operates a platform that combines machine-learning-guided capsid engineering, genetic regulatory element design, and payload optimization, and monetizes this platform through licensing deals, strategic collaborations, and internal gene therapy programs targeting rare CNS disorders.

Is Apertura Gene Therapy a public or private company?

Apertura Gene Therapy is a private company. It is classified as venture growth investor backed and is currently operating.

When was Apertura Gene Therapy founded?

Apertura Gene Therapy was founded in 2021. It employs 1 to 10 people.

Where is Apertura Gene Therapy based?

Apertura Gene Therapy is headquartered in Newyork, United Kingdom, in the Europe region.

How does Apertura Gene Therapy make money?

Four revenue lines are on record. Manufacturing Services are the primary driver. The others are academic Access Program, technology Licensing and collaboration and Development Agreements.

Who are Apertura Gene Therapy's main competitors?

Direct peers on record are 4D Molecular Therapeutics (4DMT), Voyager Therapeutics, Dyno Therapeutics, Taysha Gene Therapies and Lexeo Therapeutics. Emerging players are Latus Bio and AviadoBio. Broad incumbents are Denali Therapeutics, BioMarin Pharmaceutical and uniQure.

Does Apertura Gene Therapy have an API?

No public API is recorded for Apertura Gene Therapy.

What industry is Apertura Gene Therapy in?

Apertura Gene Therapy's product category is Gene Therapy Technology / AAV Capsid Platform. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsCollaboration and Roadmaps Key to Capsid AccessibilityApertura Gene Therapy's VP CMC & regulatory affairs, Jorge Santiago-Ortiz, discussed its TfR1 CapX AAV capsid at the Bioprocessing Summit, emphasizing manufacturability and access. The capsid has been produced in clinical batches up to 500 L, and the company offers MTAs, manufacturing advice, and contract-manufacturing connections to partners.PharmaTimesLexeo expands Friedreich ataxia pipeline with Mantle dealLexeo Therapeutics acquired Mantle Therapeutics and announced new collaborations to expand its Friedreich ataxia pipeline. The deal includes an $8.3 million upfront payment and up to $13 million in milestones, with closing expected in Q3 2026. Lexeo plans to advance one acquired programme into clinical development within its cash runway.Investing.comLexeo gains access to Apertura’s gene therapy capsid By Investing.comApertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX capsid technology for a program targeting Friedreich ataxia. The capsid is an intravenously delivered AAV designed to cross the blood-brain barrier. The agreement expands tools for evaluating approaches to address unmet needs in the disease.Investing.comLexeo gains access to Apertura’s gene therapy capsid By Investing.comApertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX capsid technology for a program targeting Friedreich ataxia. The capsid is an intravenously delivered AAV designed to cross the blood-brain barrier. The agreement expands tools for evaluating innovative approaches to address unmet needs in the disease.YahooApertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaApertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX capsid for a program treating Friedreich ataxia. The intravenously delivered capsid crosses the blood-brain barrier, and Lexeo plans to evaluate it for a less invasive CNS route after systemic administration of LX2006.PR NewswireApertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaApertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX capsid for a program treating Friedreich ataxia. The capsid is an intravenously delivered AAV designed to cross the blood-brain barrier. The partnership aims to support Lexeo's evaluation of innovative approaches for the disease.BioSpaceLexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich AtaxiaLexeo Therapeutics agreed to acquire Mantle Therapeutics and signed three collaborations to expand its Friedreich ataxia platform. The acquisition adds oral and preclinical therapies to increase frataxin in the brain, with potential consideration up to $21.3 million. LX2006's SUNRISE-FA 2 study remains on track for topline data in H2 2027.PR NewswireTSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1The TSC Alliance and Apertura Gene Therapy announced the completion of a preclinical pilot study evaluating an AAV gene therapy approach for TSC1, using Apertura's TfR1 CapX capsid designed to cross the blood-brain barrier. The TSC Alliance has committed to raise $1.76 million over the next 18 months to fund continued preclinical evaluation of TSC1 and TSC2 gene therapy programs. If the research demonstrates effectiveness, the organizations plan to advance toward IND-enabling studies and subsequent clinical trials for this rare genetic disease that causes non-cancerous tumors in multiple organs.AijournApertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood DiseasesA consortium led by the Broad Institute's Center for Therapeutic Genetics has been selected to receive funding from ARPA-H's THRIVE program to develop gene therapies for rare childhood diseases. The consortium will use Apertura Gene Therapy's novel CNS-targeted AAV capsid, TfR1 CapX, for base and prime gene editing programs targeting developmental and epileptic encephalopathies caused by mutations across more than 400 different genes affecting over three million children worldwide. Apertura has signed multiple licensing agreements for TfR1 CapX, with several programs expected to enter clinical trials within the next 12 months.PR NewswireApertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood DiseasesApertura Gene Therapy announced its participation in a consortium selected to receive funding from ARPA-H's THRIVE program to develop gene therapies for rare childhood diseases. The consortium, led by the Broad Institute's Center for Therapeutic Genetics, will use Apertura's novel CNS-targeted AAV capsid, TfR1 CapX, paired with base and prime gene editing technologies, to create a shared development platform for pediatric epilepsies and rare CNS diseases affecting over three million children worldwide. Apertura has signed multiple licensing agreements for TfR1 CapX, with several programs expected to enter clinical trials within the next 12 months.